BPC-157vsHCG

BPC-157 is a synthetic pentadecapeptide (15 amino acids) derived from a protective protein found in human gastric juice. Its mechanism of action is remarkably multifaceted, affecting multiple organ systems and healing pathways simultaneously, which is unusual for a single peptide. The primary mechanism centers on the nitric oxide (NO) system — BPC-157 modulates both constitutive (eNOS) and inducible (iNOS) nitric oxide synthase, and can either promote or inhibit NO production depending on the tissue context and injury state.

BPC-157's regenerative effects are mediated through upregulation of multiple growth factors. It increases expression of vascular endothelial growth factor (VEGF), promoting angiogenesis — the formation of new blood vessels at injury sites, which is critical for delivering oxygen and nutrients for tissue repair. It also upregulates epidermal growth factor (EGF), nerve growth factor (NGF), and hepatocyte growth factor (HGF) receptors, supporting wound healing, nerve regeneration, and organ protection respectively. In tendon and ligament injuries, BPC-157 stimulates fibroblast migration and proliferation, accelerating collagen deposition and organized tissue repair rather than scar formation.

Beyond structural healing, BPC-157 has significant effects on the central and enteric nervous systems. It modulates dopaminergic, serotonergic, GABAergic, and opioid systems, which may explain reported effects on mood, gut function, and pain perception. It protects endothelial function, counteracts the effects of NSAIDs on the gastric mucosa, and has demonstrated cytoprotective effects in models of liver, brain, heart, and intestinal damage. The peptide also interacts with the FAK-paxillin pathway, which is central to cell adhesion and migration during wound healing. Its stability in gastric juice — unusual for a peptide — enables oral administration, making it one of the few peptides effective by both injectable and oral routes.

Human Chorionic Gonadotropin is a glycoprotein hormone composed of two non-covalently linked subunits: an alpha subunit (92 amino acids, shared with LH, FSH, and TSH) and a unique beta subunit (145 amino acids) that confers biological specificity. HCG's beta subunit shares approximately 85% amino acid homology with the LH beta subunit, allowing HCG to bind and activate the LH/CG receptor (LHCGR) on Leydig cells in the testes with equal or greater affinity than LH itself.

LHCGR is a Gs-coupled GPCR that activates adenylyl cyclase upon ligand binding, increasing intracellular cAMP. cAMP activates PKA, which phosphorylates the steroidogenic acute regulatory protein (StAR). Phosphorylated StAR transports cholesterol from the outer to the inner mitochondrial membrane — the rate-limiting step in steroid hormone synthesis. Inside the mitochondria, the cholesterol side-chain cleavage enzyme (CYP11A1) converts cholesterol to pregnenolone, which then undergoes a series of enzymatic conversions (through the delta-4 or delta-5 pathway) to produce testosterone. This entire steroidogenic cascade occurs within Leydig cells and produces intratesticular testosterone concentrations 50-100 times higher than serum levels — essential for spermatogenesis in the adjacent seminiferous tubules.

HCG's longer half-life compared to LH (24-36 hours vs 20 minutes) is due to its heavily glycosylated beta subunit, which reduces renal clearance. This extended duration makes it practical for intermittent injection protocols. In addition to stimulating testosterone, HCG activates aromatase (CYP19A1) in Leydig cells, converting some of the produced testosterone to estradiol — which is why HCG use can elevate estrogen levels, potentially causing gynecomastia and water retention. HCG also maintains Sertoli cell function (which supports spermatogenesis) through indirect paracrine signaling from testosterone-producing Leydig cells. The physical preservation of testicular volume during TRT is a direct result of maintained Leydig cell activity and seminiferous tubule function.